Search Results

SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-40.

SeqLL Inc., announced the decision of its Board of Directors to cancel the special cash dividend and stock dividend that it intended to make to its common stockholders in connection with, and subject to, the consummation of its planned acquisition of Lyneer Investments LLC and the disposition of its current business operations.

SeqLL Inc. announced its operating and financial results for the first quarter ended March 31, 2023.

SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL; SQLLW), a technology company providing life sciences instrumentation and research services, today announced its operating and financial results for the fourth quarter and year ended December 31, 2022.

SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced the establishment of a two-year Cooperative Research and Development Agreement with the U.S. Department of Justice’s Federal Bureau of Investigation.

SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced that Brian Paras has joined the company as Chief Business Officer.

SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), a technology company providing life sciences instrumentation and research services, today announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

SeqLL Inc. (“SeqLL” or the “Company”) (NASDAQ: SQL), today announced the peer-reviewed publication of a new microscopy-based epitranscriptomic method powered by SeqLL’s tSMS platform in the August issue of Cell Report Methods.

SeqLL Inc. announced a new study demonstrating early cancer detection using SeqLL’s single-molecule technology was published in the peer-reviewed journal Nature Biotechnology.

SeqLL Inc., a technology company providing life sciences instrumentation and research services, announced the closing of its previously announced registered direct offering of 2,000,000 shares of common stock at a purchase price of $0.90 per share of common stock.